Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Naxozol is a combination product of naproxen, a non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, a proton pump inhibitor which is designed to improve symptoms and reduce risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The purpose of this study is to investigate whether naxozol protects the gastrointestinal tract effectively compared to celecoxib, a COX-2 inhibitor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin

NCT00175032

Osteoarthritis Peptic Ulcer

COMPLETED PHASE3

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

NCT01063920

Osteoarthritis

COMPLETED PHASE2/PHASE3

Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee

NCT00652808

Osteoarthritis Knee

COMPLETED PHASE3

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

NCT00141102

Osteoarthritis Arthritis, Rheumatoid

COMPLETED PHASE4

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

NCT00392080

Osteoarthritis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 10 orthopedic investigators will participate in this study. The effectiveness in gastro-protection of study drug will be assessed by Leeds Dyspepsia Questionnaire (LDQ). The orthopedic investigators will be trained with this questionnaire administration by an expert gastroenterologist prior to starting this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Group

Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks

Group Type EXPERIMENTAL

Naproxen/Esomeprazol 500/20mg

Intervention Type DRUG

Tablet, b.i.d.

Comparator-Placebo

Intervention Type DRUG

Capsule (which is identical to Celebrex), o.d.

Comparator Group

Celecoxib 200mg and Naxozol-Placebo for 12 weeks

Group Type ACTIVE_COMPARATOR

Celecoxib 200mg

Intervention Type DRUG

Capsule, o.d.

Naxozol-Placebo

Intervention Type DRUG

Tablet (which is identical to Naxozol), b.i.d.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naproxen/Esomeprazol 500/20mg

Tablet, b.i.d.

Intervention Type DRUG

Celecoxib 200mg

Capsule, o.d.

Intervention Type DRUG

Naxozol-Placebo

Tablet (which is identical to Naxozol), b.i.d.

Intervention Type DRUG

Comparator-Placebo

Capsule (which is identical to Celebrex), o.d.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Naxozol Celebrex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Koreans given informed consent
* Patients who have ability of reading comprehension and completing questionnaires (EQ-5D and VAS)and have willingness to follow-up 12 weeks
* Patients with osteoarthritis symptoms confirmed by his/her medical history and with pain-VAS of 40 and more

Exclusion Criteria

* Patients who participate into other interventional study or had participated within 30 days before screening
* Alcohol or drug abuse within 6 months or alcohol consumption of 21 units and more in a week
* Peptic ulcers accompanied with a complication such as bleeding, perforation, penetration or gastric outlet obstruction within 5 years, or a history of active peptic ulcer or peptic ulcer without a complication within 6 months at screening
* Patients who are known with Helicobacter pylori infection but have not received any bacteriostatic treatment
* Known gastroesophageal reflux disease (GERD)
* Any following joint diseases which may significant effect to the efficacy and safety assessments: septic arthritis, inflammatory joint arthritis such as rheumatoid arthritis, gout, recurrent pseudo-pain, Paget's disease, joint fracture, joint ochronosis, acromegaly, hematochromatosis, Wilson's disease, primary osteochondrosis, Ehlers Danlos Syndrome, or other collagen genetic disorder
* Patients who are scheduled admissions to hospital for elective surgery during this study
* History of gastrointestinal cancer
* Gastrointestinal disorders related to drug malabsorption
* Gastrointestinal bleeding, cerebral bleeding, other bleeding disorders, or severe hematological disorders
* Clinically significant diseases such as moderate or severe liver diseases (Child Pough Class II or more), severe heart failure or a history of coronary artery bypass graft (CABG), severe kidney diseases (CrCl\<30ml/min)
* Know allergy experiences with any ingredient of study drugs or with other NASIDs or protocol pump inhibitors (PPIs)
* Patients who had had a joint surgery for osteoarthritis within 1 year
* Women of childbearing potential who do not agree with clinically appropriate contraception during this study

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seong-Hwan Moon

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seong-Hwan Moon, M.D., Ph.D.

Role: STUDY_CHAIR

Severance Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.